Non-Opioid Pain Treatment Market Size to Hit USD 78.01 Bn by 2030

According to Nova one advisor, the global Non-opioid Pain Treatment market size is expected to hit around USD 78.01 billion by 2030 from valued at USD 38.94 billion in 2021 and growing at a CAGR of 8.60% from 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7081

Key Takeaways:

• By Drug Class, the U.S. Non-opioid Pain Treatment market was valued at USD 13.9 Billion in 2021 and expected to witness growth at a CAGR of 7.6% from 2022 to 2030.
• In 2021, the NSAIDs segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period owing to the high demand for pain treatment and commercialization of multiple NSAIDs in recent years
• Chronic pain was the accounted for highest share in 2021. Factors such as increasing product approvals, the high incidence rate of chronic pain, and high R&D initiatives for launching innovative NSAIDs products are leading to its dominance
• Based on route of administration type, the oral segment accounted for the highest share in 2021 owing to the easy administration and wide availability of orally administered NSAIDs products in the market
• Based on the distribution channel, retail pharmacies are expected to dominate the market with a 53.98% share in 2021. This dominance can be attributed to the presence of a large number of generic NSAIDs and their easy accessibility to patients due to the large presence of retail pharmacies network
• Asia Pacific region is expected to experience the fastest growth over the forecast period owing to an increase in penetration of NSAIDs products, rise in disposable income, and high disease prevalence of inflammatory diseases in developing countries

Report Scope of the Non-opioid Pain Treatment Market

Ask here for more customization study@  https://www.novaoneadvisor.com/report/customization/7081

The growth can be attributed to an increase in the prevalence of inflammatory diseases coupled with the robust product pipeline of novel non-opioid analgesics. According to the Centers for Disease Control and Prevention (CDC), around 32.5 million people are living with osteoarthritis condition in the U.S. In addition, according to the Spondylitis Association of America, about 3.2 million adult people in the U.S. have some form of Spondyloarthritis. 

Initiatives are undertaken by government & nonprofit organizations to promote the usage of safer alternatives to opioids such as NSAIDs to address the increasing demand for pain relieving medicines. For instance, in February 2022, the U.S.FDA issued draft guidelines to provide recommendations to pharmaceutical companies for developing NSAIDs for the treatment of acute pain lasting for 30 days. This initiative was a part of the government’s “HHS Overdose Prevention Strategy” which focuses on the prevention, reduction, treatment, and recovery of patients from an opioid overdose. Such an initiative is projected to fuel demand for NSAID drugs over the forecast period. 

Key market players are aggressively developing innovative techniques to meet the growing demand for NSAIDs for the management of pain. For instance, in June 2021, the University of Arizona developed oxytocin analogs for the treatment of patients suffering from. It is a bioavailable non-opioid pain relief product with the potential for inhaled administration. The development of such an innovative product is anticipated to drive non-opioid analgesics treatment market growth. 

In September 2022, the U.S. FDA recommended avoiding of non-opioid analgesics treatment in pregnancy at 20 weeks due to the high chances of kidney problems in unborn babies. Such initiatives from governments may limit the prescription of NSAIDs, thereby, restraining non-opioid pain treatment market growth. 

Companies are adopting strategies such as new product development, launches, and partnerships to increase the penetration of non-opioid analgesic products. For instance, in March 2022, Vertex Pharmaceuticals announced positive results of its phase 2 clinical trial non-opioid pill that showed a significant reduction in post-operative acute pain. Successful completion of trial and subsequent approval of products is anticipated to drive non-opioid analgesics treatment market growth over the forecast period. 

The market is highly competitive and the competition in the market is expected to be high during the forecast period due to the presence of a large number of players. Key companies manufacturing generic NSAID products include GSK plc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson & Johnson Services, Inc., amongst others. 

Drug Class Insights

The nonsteroidal anti-inflammatory drugs (NSAIDs) segment dominated the industry and accounted for a revenue share of 57.2% in 2021. The segment is anticipated to maintain its dominance over the forecast period owing to the wide availability of effective NSAID medications with low costs and safer alternatives to opioids for treatment. Some of the NSAIDs that are globally used include Cambia, Cataflam, Dyloject, Zipsor, Zorvolex, Advil, Motrin, and Aleve, among others.

In addition, advancement in drug formulation and increased penetration of new products in the market contributes to the continued dominance over the forecast period. For instance, in March 2020, the U.S. Food and Drug Administration (FDA) approved Advil Dual Action for the treatment of patients with dental pain. This drug was a combination of acetaminophen and ibuprofen to be available over the counter (OTC) for dental patients in the U.S.

The others segment is anticipated to witness the fastest growth over the forecast period owing to the wide availability of anticonvulsants and antimigraine drugs coupled with the presence of potential pipeline candidates to address the unmet needs for non-opioids-based therapies. For instance, Grünenthal is currently engaged in the development of late staged pipeline products such as RTX (resiniferatoxin), MPC-06-ID, and Qutenza (label expansion) for the treatment of pain associated with osteoarthritis of the knee, chronic low back pain, and post-surgical neuropathic pain respectively.

Pain Type Insights

The chronic pain segment dominated with a revenue share of 38.1% in 2021 owing to the increasing prevalence of chronic pain such as neuropathic pain and pain associated with inflammatory conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and others coupled with increased demand for non-opioid analgesic drugs. According to the National Library of Medicine, approximately 7% of the world’s population suffers from neuropathic pain. Thus, the increasing prevalence of diseases is anticipated to increase the prescription rate for NSAID medicines.

The others segment is estimated to witness lucrative growth over the forecast period. The growth of the segment can be attributed due to increasing unintentional or accidental injuries and acute pain. According to the CDC, around 25.8 million visited physician’s offices due to accidental injuries. Hence, increasing accidental injuries subsequently increases demand for pain relief products such as non-opioid analgesics for their pain treatment, thereby, driving the market growth.

Route Of Administration Insights

The oral segment dominated the non-opioid analgesics market and accounted for a revenue share of 48.0% in 2021 owing to the approval and launch of new oral NSAIDs for pain management. Key oral non-opioid analgesics drug prescribed by physicians to their patients for pain management includes Celebrex (celecoxib), Cambia, Cataflam, Dyloject, Zipsor, and Zorvolex (diclofenac potassium), Anaprox, Anaprox Ds, Ec-Naprosyn, Naprosyn, Naprelan, and Treximet (naproxen sodium), Lodine (etodolac), Nalfon (fenoprofen), Motrin & Advil (ibuprofen), and Daypro (oxaprozin), among others. Advil is available in tablet formulation and administered orally to relieve pain from various conditions such as muscle aches, dental pain, headache, and menstrual cramps.

The injectable segment is estimated to exhibit the fastest growth rate of 9.8% over the forecast period, owing to the factors such as technological advancements in drug delivery and the commercialization of novel IV products, and the increasing usage of local anesthetic products for surgical procedures. For instance, in February 2021, the U.S. FDA approved the first and only acetaminophen injection developed by B Braun Medical for the treatment of pain conditions caused by various diseases.

Distribution Channel Insights

The retail pharmacy segment dominated the non-opioid pain treatment market and accounted for a revenue share of 54.0% in 2021, owing to the wide availability of non-opioid analgesic drugs and easy accessibility to medicines for patients. The major retail pharmacies which provide non-opioid analgesics are Walgreens Boots Alliance, Inc., CVS Health, Ahold Delhaize, Rite Aid Corp., and Albertsons Companies, Inc. According to the Consumer Healthcare Products Association (CHPA) the sales of OTC analgesics external & internal reached USD 1,286 million & USD 4,640 million respectively in 2021.

The hospital pharmacy segment is the second largest revenue-generating segment in 2021. This can be attributed due to the widespread use of non-opioid analgesics for the treatment of hospitalized patients. In addition, the rise in the number of hospitals that perform various ambulatory surgeries for the treatment of various diseases would escalate the growth of the segment over the forecast period.

Regional Insights

North America dominated the non-opioid pain treatment industry and accounted for a revenue share of 39.10% in 2021. This dominance can be attributed to the high demand for NSAIDs, proactive government measures for limiting opioid use, improvements in healthcare infrastructure, and the presence of major players. Favorable government initiatives and reimbursement policies are likely to drive market growth.

Asia Pacific region is estimated to witness the fastest growth rate over the forecast period. The high growth rate can be attributed to initiatives undertaken by key players to develop and commercialize non-opioid analgesics in the region. In July 2022, NeuroFront Therapeutics and Novaremed AG announced an exclusive licensing and collaboration agreement for the commercialization of NRD.E1 to treat patients with neuropathic pain in Singapore and Greater China.

Some of the prominent players in the Non-opioid Pain Treatment Market include:

• Novartis AG
• Teva Pharmaceutical Industries Limited
• Dr. Reddy’s Laboratories Ltd
• Sun Pharmaceutical Industries Ltd
• GSK plc.
• Pfizer Inc.
• Perrigo Company plc,
• LNK International, Inc.
• Cipla Inc.
• Johnson & Johnson Services, Inc.
• Pacira Pharmaceuticals, Inc.
• Pierrel 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Non-opioid Pain Treatment market

• Drug Class
  • NSAIDs
    • Selective COX-2 Inhibitors
    • Non-Selective NSAIDs
  • Acetaminophen
  • Local Anesthetics
  • Others
• Pain Type
  • Chronic Pain
    • Neuropathic Pain
    • Inflammatory Conditions
  • Post-operative Pain
  • Cancer Pain
  • Others
• Route of Administration
  • Oral
  • Injectable
  • Topical
  • Others
• Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7081

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/